A recent article in The Wall Street Journal detailed the work of GHR partner C2N Diagnostics and the Alzheimer’s Drug Discovery Foundation, along with the groundbreaking research of C2N co-founder, Dr. Randall Bateman.

From The Wall Street Journal:

"The new Alzheimer’s blood tests, meanwhile, are meant to help determine if memory loss and brain aging are due to early stages of the disease. These tests, available with a doctor’s prescription, include one from lab giant Quest Diagnostics Inc. and one developed at Washington University School of Medicine in St. Louis and licensed to C2N Diagnostics, a company founded by some researchers at the university. The tests have been shown to accurately assess whether amyloid plaques have started to accumulate in the brain based on the ratio of levels of two proteins in the blood. "

Read more.

From The Florida Times-Union:

"The Mayo Clinic in Jacksonville has received a $41 million federal grant for a potentially groundbreaking study to better understand Alzheimer's disease and how the brain disorder affects people of different ethnic groups.  The five-year grant from the National Institute on Aging, part of the National Institutes of Health, is one of the largest in the Jacksonville clinic's history. It will involve at least 80 researchers, from Mayo, Indiana University and 11 other U.S. institutions, and data from thousands of patients.

"Alzheimer's disease afflicts patients from African-American backgrounds at a rate twice as high as that in white populations. For Latino Americans, the risk is one-and-a-half times greater than that in white populations. These populations have traditionally been understudied for Alzheimer's disease, leading to a major knowledge gap. When we try to understand the molecular underpinnings, the disease fingerprints, we need to understand it for all of us to be able to identify biomarkers and therapies." Dr. Nilüfer Ertekin-Taner, a Mayo Clinic professor of neuroscience and neurology and physician-scientist who is a co-principal investigator of the study."

Through our support of this and other studies, GHR lives out its commitment to helping patients and families live full lives in a world where Alzheimer’s Disease becomes a preventable condition. GHR aims to halt Alzheimer's disease prior to the onset of cognitive symptoms by supporting new diagnostic tools and prevention trials. Learn more about our work on Alzheimer’s prevention.